Ogkologos

4396 ΔΗΜΟΣΙΕΥΣΕΙΣ 0 ΣΧΟΛΙΑ

Benefit in OS with Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant...

Ogkologos - 4 Οκτωβρίου, 2024

Evidence for the Utility of ctDNA Monitoring for Recurrence After CRC...

Ogkologos - 3 Οκτωβρίου, 2024

Combination Chemo Helps People with Leiomyosarcoma Live Longer

Ogkologos - 2 Οκτωβρίου, 2024

FDA Approves Atezolizumab and Hyaluronidase-tqjs for Subcutaneous Injection

Ogkologos - 2 Οκτωβρίου, 2024

Adjuvant Pembrolizumab Plus Chemotherapy Improves DFS in Patients with Newly-Diagnosed, High-Risk...

Ogkologos - 1 Οκτωβρίου, 2024

EMA Recommends Granting a Marketing Authorisation for Mirvetuximab Soravtansine

Ogkologos - 30 Σεπτεμβρίου, 2024

Substantial and Durable Overall and Intracranial Activity of Trastuzumab Deruxtecan in...

Ogkologos - 27 Σεπτεμβρίου, 2024

Jaw Problems Linked to Bone-Modifying Drugs Not as Rare as Once...

Ogkologos - 26 Σεπτεμβρίου, 2024

No Survival Benefit from Adding Preoperative Chemoradiotherapy to Perioperative Chemotherapy in...

Ogkologos - 26 Σεπτεμβρίου, 2024

Adjuvant Pembrolizumab Prolongs DFS Among Patients with High-Risk Muscle Invasive Urothelial...

Ogkologos - 25 Σεπτεμβρίου, 2024

1...686970...440 Σελίδα 69 από 440

MOST POPULAR

ESMO Congress 2021, 16-21 September

2 Σεπτεμβρίου, 2021

Trial Results Confirm Effectiveness of Atezolizumab Against a Rare Sarcoma

20 Οκτωβρίου, 2023

New Radiation Therapy Won’t Leave Breast Cancer Patients with Unwanted Tattoo...

13 Σεπτεμβρίου, 2019

Neoadjuvant PD1/PD-L1 Blockade Combined with Chemotherapy Associated with High Resectability and...

3 Ιουνίου, 2025

Φόρτωση περισσοτέρων

Benefit in OS with Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant...

Evidence for the Utility of ctDNA Monitoring for Recurrence After CRC...

Combination Chemo Helps People with Leiomyosarcoma Live Longer

FDA Approves Atezolizumab and Hyaluronidase-tqjs for Subcutaneous Injection

Adjuvant Pembrolizumab Plus Chemotherapy Improves DFS in Patients with Newly-Diagnosed, High-Risk...

EMA Recommends Granting a Marketing Authorisation for Mirvetuximab Soravtansine

Substantial and Durable Overall and Intracranial Activity of Trastuzumab Deruxtecan in...

Jaw Problems Linked to Bone-Modifying Drugs Not as Rare as Once...

No Survival Benefit from Adding Preoperative Chemoradiotherapy to Perioperative Chemotherapy in...

Adjuvant Pembrolizumab Prolongs DFS Among Patients with High-Risk Muscle Invasive Urothelial...

MOST POPULAR

ESMO Congress 2021, 16-21 September

Trial Results Confirm Effectiveness of Atezolizumab Against a Rare Sarcoma

New Radiation Therapy Won’t Leave Breast Cancer Patients with Unwanted Tattoo...

Neoadjuvant PD1/PD-L1 Blockade Combined with Chemotherapy Associated with High Resectability and...

HOT NEWS

Women Over Age 65 Years with Pathogenic Variants in Cancer Predisposition...

EMA Recommends Extension of Therapeutic Indications for Encorafenib and Binimetinib

Air Is Life: The Navajo Nation’s Historic Commercial Tobacco Ban

Being Diagnosed With a Childhood Cancer As an Adult Led Me...

ΔΗΜΟΦΙΛΕΊΣ ΘΈΣΕΙΣ

ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ)

ΣΤΑΤΙΣΤΙΚΑ

ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ

ΔΗΜΟΦΙΛΗ ΚΑΤΗΓΟΡΙΑ